ClinicalTrials.gg
RecruitingNCT06030349REFRESHEDUpdated Feb 12, 2024

Clinical Outcomes From Treatment and Evaluation of Obstructive Sleep Apnoea in Children With Down Syndrome

An observational study in Obstructive Sleep Apnea, Down Syndrome and Quality of Life, sponsored by Children's Health Ireland. Recruiting at 6 sites in 2 countries. Open to participants aged 6 Months to 16 Years. Per ClinicalTrials.gov, last updated 2024-02-12.

Sponsored by Children's Health Ireland · Observational

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
6 Months to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom — 9 open to participants now, 13 under way, none of them phase 3. Sleep Apnea, Obstructive · United Kingdom.

Planned enrollment
9th of 28
200 · median 102
Started
2022
with 4 others
Observational
28 of 54
6 open now
Primary completion
2027-11
later than 9 of 12 live
Registered
41st of 54
by date

Among the 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom, this one is the 9th largest by planned enrollment of the 28 observational ones that give a count, is one of 5 that started in 2022, is one of 28 observational ones, reaches primary completion later than 9 of the 12 other live ones, and was the 41st registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

9 of the 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 6 Months to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the use of non-invasive ventilation for treatment of obstructive sleep apnoea syndrome in children with Down Syndrome. The main questions it aims to answer are:

  • What is the impact of non-invasive ventilation on sleep behaviours and quality of life?
  • What barriers are faced by children and their families in establishing tolerance to non-invasive ventilation?

Participants will be asked to complete questionnaires before and after starting treatment. Researchers will compare this data with the results of sleep studies and non-invasive ventilator downloads recorded as part of standard medical care. A sub-group of up to 20 participants will be invited to take part in 45-60 minute interviews exploring expectations, experiences and barriers encountered during non-invasive ventilation therapy.

Read the detailed description

Our aim is to examine the impact of non-invasive ventilation for treatment of obstructive sleep apnoea syndrome in children with Down Syndrome on behavioural and quality of life outcomes and to establish the specific barriers experienced in establishing adherence to treatment.

Information from clinical assessment, sleep studies and device downloads recorded as part of standard care will be combined with questionnaire data to assess for changes in behaviour and quality of life. All participants will undergo questionnaire assessment of barriers experienced. A sub-group of up to 20 participants will be invited to take part in 45-60 minute semi-structured interviews exploring expectations, experiences and barriers encountered.

03

Conditions studied

  • Obstructive Sleep Apnea
  • Down Syndrome
  • Quality of Life
  • Behavior
  • Adherence, Treatment
04

Who can participate

Ages eligible
6 Months to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children with Down Syndrome referred for evaluation for suspected sleep disordered breathing

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with a confirmed diagnosis of Down Syndrome where a clinical decision has been made to initiate respiratory support with non-invasive ventilation.
  • Obstructive Apnoea Hypopnoea Index > 2 episodes/hour or where sleep disordered breathing symptoms occur in combination with an Apnoea Hypopnoea Index > 1 episode/hr. - English language proficiency.
  • Age ≥ 4 months at the commencement of therapy.

Exclusion criteria

Exclusion Criteria:

  • Individuals not willing to comply with study procedures or assessments.
  • Individuals for whom ventilatory support devices are already prescribed and those with artificial airways.
  • Individuals on clinical trials of support therapies.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Standard

    In addition to data from clinical assessment, sleep studies and non-invasive ventilator downloads recorded as part of standard care participants will undergo questionnaire assessment of behaviour, quality of life and barriers to tolerating treatment. Participants aged 3 years and above will receive the Child Sleep Habits Questionnaire, Obstructive Sleep Apnoea-18 questionnaire and Adherence Barriers to CPAP (Continuous Positive Airway Pressure) Questionnaire. Participants aged 6 months to 3 years will receive the Brief Infant Sleep Questionnaire, Infant Toddler Quality of Life - Short Form 47, Obstructive Sleep Apnoea -18 Caregiver Concern Domain and a modified version of the Adherence Barriers to CPAP Questionnaire.

    Device: Non-invasive ventilation

  • Advanced

    In addition to all elements of the standard testing group, a sub-group of up to 20 participants will be invited to take part in 45-60 minute semi-structured interviews exploring expectations, experiences and barriers encountered.

    Device: Non-invasive ventilation

Interventions

  • DeviceNon-invasive ventilation

    Non-invasive ventilation

06

What researchers measure

Primary outcomes

  1. To determine the effect of treatment of obstructive sleep apnoea syndrome with non-invasive ventilation on quality of life in children with Down Syndrome > 3 years.

    Change in Obstructive Sleep Apnoea - 18 scores (Range 0- 126, Higher scores indicating worse quality of life) from baseline will be used to evaluate for improvement in sleep related breathing specific quality of life in children \>3 years. Sleep disturbance, physical suffering, emotional distress, daytime problems and caregiver concern subscales will also be evaluated for change.

    Time frame: Prior to and following 8 weeks attempted initiation of non-invasive ventilation treatment

  2. To determine the effect of treatment of obstructive sleep apnoea syndrome with non-invasive ventilation on quality of life in children with Down Syndrome < 3 years.

    Change in Infant Toddler Quality of Life - Short Form 47 scores (Range 0 - 100, Higher scores indicating greater quality of life) from baseline will be used to evaluate for improvement in sleep related breathing specific quality of life in children \< 3 years. Infant and parent subscales will also be evaluated for change.

    Time frame: Prior to and following 8 weeks attempted initiation of non-invasive ventilation treatment

  3. To determine the effect of treatment of obstructive sleep apnoea syndrome with non-invasive ventilation on caregiver concerns regarding sleep disordered breathing for caregivers of children with Down Syndrome < 3 years.

    Change in Caregiver-concern domain of the Obstructive Sleep Apnoea - 18 (Range 0 - 28, Higher scores indicating worse quality of life) from baseline will be used to evaluate for change in caregiver concern regarding sleep disordered breathing.

    Time frame: Prior to and following 8 weeks attempted initiation of non-invasive ventilation treatment

  4. To determine the effect of treatment of obstructive sleep apnoea with non-invasive ventilation on sleep behaviours in children with Down Syndrome > 3 years.

    Change in Child Sleep Habits Questionnaire scores (Range 0 - 97, Higher scores indicating greater sleeping difficulties) from baseline will be used to evaluate for overall improvement in sleep behaviours in children \> 3 years. Bedtime resistance, sleep onset delay, sleep duration, sleep anxiety, night waking, parasomnia, sleep disordered breathing and daytime sleepiness subscales will also be evaluated for change.

    Time frame: Prior to and following 8 weeks attempted initiation of non-invasive ventilation treatment

  5. To determine the effect of treatment of obstructive sleep apnoea with non-invasive ventilation on sleep behaviours in children with Down Syndrome < 3 years.

    Change in Brief Infant Sleep Questionnaire scores (Range 0 - 100, Lower scores indicating greater sleeping difficulties) from baseline will be used to evaluate for overall improvement in sleep behaviours in children \< 3 years. Infant sleep, parent perception and parent behaviour subscales will also be evaluated for change.

    Time frame: Prior to and following 8 weeks attempted initiation of non-invasive ventilation treatment

  6. To establish the specific barriers to adherence faced by children > 3 years with Down Syndrome and their caregivers when starting non-invasive ventilation for the treatment of obstructive sleep apnoea syndrome

    Quantitative assessment of barriers encountered in establishing adherence will be evaluated using the Continuous Positive Airway Pressure Questionnaire (Range 29-145, Higher scores indicating greater barriers to adherence) for children \> 3 years. Behaviours/belief/environment, emotional and physical subscales will also be evaluated for change.

    Time frame: Prior to and following 8 weeks attempted initiation of non-invasive ventilation treatment

  7. To establish the specific barriers to adherence faced by children < 3 years with Down Syndrome and their caregivers when starting non-invasive ventilation for the treatment of obstructive sleep apnoea syndrome

    Quantitative assessment of barriers encountered in establishing adherence will be evaluated using the Modified Continuous Positive Airway Pressure Questionnaire (Range 27 - 135, Higher scores indicating greater barriers to adherence) for children \< 3 years. This is a non-validated questionnaire developed by our research group.

    Time frame: Prior to and following 8 weeks attempted initiation of non-invasive ventilation treatment

  8. Assessment of expectations, experiences and barriers experienced by families in the treatment of obstructive sleep apnoea syndrome with non-invasive ventilation

    Qualitative assessment of expectations, experiences and barriers experienced during non-invasive ventilation treatment will be explored through semi-structured interviews to add nuance to the outcomes around efficacy of treatment, quality of life, behaviour, and treatment adherence

    Time frame: After 8 weeks of attempted initiation of non-invasive ventilation

07

Study locations

2 of 6 sites recruiting
  • Trinity College Dublin
    Dublin, D02 PN40, Ireland
    Recruiting
    • Ruth Monaghan · Contact
    • Elizabeth Nixon · Principal investigator
    • Ruth Monaghan · Sub investigator
  • Children's Health Ireland
    Dublin, D12 N512, Ireland
    Recruiting
    • Roy G Stone · Contactrefreshed@olchc.ie · 0035314282626
    • Sheila Javadpour · Principal investigator
    • Roy G Stone · Sub investigator
    • Lisa Farrell · Sub investigator
    • Anne-Marie Casey · Principal investigator
  • Royal Belfast Hospital for Sick Children
    Belfast, BT12 6BA, United Kingdom
    Not yet recruiting
    • Dara O'Donoghue · Contact
    • Dara O'Donoghue · Principal investigator
    • Barbara Maxwell · Sub investigator
    • Ruth Harte · Sub investigator
  • Birmingham Children's Hospital
    Birmingham, B4 6NH, United Kingdom
    Not yet recruiting
    • Priti Kenia · Contact
    • Priti Kenia · Principal investigator
  • Royal Hospital for Children & Young People
    Edinburgh, EH16 4TJ, United Kingdom
    Not yet recruiting
    • Florian Gahleitner · Contact
    • Florian Gahleitner · Principal investigator
  • Southampton Children's Hospital
    Southampton, SO16 6YD, United Kingdom
    Not yet recruiting
    • Hazel Evans · Contact
    • Catherine M Hill · Contact
    • Hazel Evans · Principal investigator
    • Catherine M Hill · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Nov 2027, 60 months after the start.

Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 60 months is above that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2023
First posted
Sep 11, 2023
StartActual
Nov 28, 2022
Primary completionEst.
Nov 28, 2027
CompletionEst.
Dec 28, 2027
Last update
Feb 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06030349
Lead sponsor
Children's Health Ireland
Collaborators
University of Edinburgh, Birmingham Children's Hospital, Belfast Health and Social Care Trust, University Hospital Southampton NHS Foundation Trust, University of Dublin, Trinity College
Responsible party
Sheila Javadpour (Clinical Lead for Respiratory Sleep Medicine, Children's Health Ireland) — Principal investigator
First posted
Sep 11, 2023
Start date
Nov 28, 2022
Primary completion
Nov 28, 2027 (estimated)
Completion
Dec 28, 2027 (estimated)
Last update
Feb 12, 2024

Study contacts

Roy G Stone
Contact
refreshed@olchc.ie
0035314282626 ext. 604
Sheila Javadpour
principal investigator · Children's Health Ireland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion